Zasocitinib

Overview of the drug Zasocitinib

Zasocitinib
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Zasocitinib is a Janus kinase (JAK) inhibitor that is currently under investigation for the treatment of various autoimmune diseases. It is being developed by Takeda Pharmaceutical Company.

Mechanism of Action

Zasocitinib functions as a selective inhibitor of the Janus kinase 1 (JAK1) enzyme. JAK1 is a critical component of the JAK-STAT signaling pathway, which is involved in the transmission of extracellular signals from various cytokines and growth factors to the cell nucleus, influencing gene expression. By inhibiting JAK1, zasocitinib can modulate the immune response, making it a potential therapeutic option for conditions characterized by overactive immune responses.

Clinical Development

Zasocitinib is currently in clinical trials for the treatment of several autoimmune conditions, including atopic dermatitis, psoriasis, and rheumatoid arthritis. These trials are designed to evaluate the efficacy, safety, and tolerability of the drug in human subjects.

Atopic Dermatitis

In patients with atopic dermatitis, the immune system is hyperactive, leading to inflammation and skin lesions. Zasocitinib's ability to inhibit JAK1 may help reduce the inflammatory response and alleviate symptoms in affected individuals.

Psoriasis

Psoriasis is another autoimmune condition characterized by rapid skin cell proliferation and inflammation. By targeting the JAK-STAT pathway, zasocitinib may help control the excessive immune activity that contributes to the disease.

Rheumatoid Arthritis

In rheumatoid arthritis, the immune system attacks the joints, causing pain and swelling. Zasocitinib's role in modulating immune responses could potentially reduce joint inflammation and improve patient outcomes.

Pharmacokinetics

The pharmacokinetic profile of zasocitinib includes its absorption, distribution, metabolism, and excretion. As a small molecule inhibitor, it is designed to be orally bioavailable, allowing for convenient administration. The drug's metabolism and elimination pathways are currently being studied to optimize dosing regimens.

Safety and Tolerability

The safety profile of zasocitinib is being closely monitored in clinical trials. Common adverse effects associated with JAK inhibitors include increased risk of infections, changes in blood cell counts, and potential impacts on liver function. Ongoing studies aim to further elucidate the safety and tolerability of zasocitinib in diverse patient populations.

Related Pages

• Janus kinase inhibitors
• Autoimmune disease
• Atopic dermatitis
• Psoriasis
• Rheumatoid arthritis